

By: Representative Hobgood-Wilkes

To: Drug Policy

COMMITTEE SUBSTITUTE  
FOR  
HOUSE BILL NO. 1685

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,  
2 TO INCLUDE SEVEN SUBSTANCES AS SCHEDULE I CONTROLLED SUBSTANCES  
3 BECAUSE THESE DRUGS HAVE NO LEGITIMATE MEDICAL USE AND HAVE A HIGH  
4 POTENCY WITH GREAT POTENTIAL TO CAUSE HARM; TO AMEND SECTION  
5 41-29-119, MISSISSIPPI CODE OF 1972, TO INCLUDE DARIDOREXANT AND  
6 ZURANOLONE AS SCHEDULE IV CONTROLLED SUBSTANCES BECAUSE THESE  
7 DRUGS HAVE A CURRENTLY ACCEPTED MEDICAL USE AND A LOW POTENTIAL  
8 FOR ABUSE THAT MAY LEAD TO LIMITED PHYSICAL DEPENDENCE OR  
9 PSYCHOLOGICAL DEPENDENCE RELATIVE TO THE DRUGS OR OTHER SUBSTANCES  
10 IN SCHEDULE III; TO REMOVE FENFLURAMINE AS A SCHEDULE IV  
11 CONTROLLED SUBSTANCE; TO AMEND SECTION 41-29-121, MISSISSIPPI CODE  
12 OF 1972, TO INCLUDE GANAXOLONE AS A SCHEDULE V CONTROLLED  
13 SUBSTANCE; AND FOR RELATED PURPOSES.

14 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

15 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is  
16 amended as follows:

17 41-29-113.

18 **SCHEDULE I**

19 (a) Schedule I consists of the drugs and other substances,  
20 by whatever official name, common or usual name, chemical name, or  
21 brand name designated, that is listed in this section.

22 (b) **Opiates.** Unless specifically excepted or unless listed  
23 in another schedule, any of the following opiates, including their



24 isomers, esters, ethers, salts and salts of isomers, esters and  
25 ethers, whenever the existence of these isomers, esters, ethers  
26 and salts is possible within the specific chemical designation:

27 (1) Acetyl-alpha-methylfentanyl  
28 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

29 (2) Acetylmethadol;

30 (3) Acetyl fentanyl  
31 (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

32 (4) Acryl fentanyl  
33 (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), also known as  
34 acryloylfentanyl;

35 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
36 cyclohexylmethyl]benzamide);

37 (6) Allylprodine;

38 (7) Alphacetylmethadol, except levo-alphacetylmethadol  
39 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

40 (8) Alphameprodine;

41 (9) Alphamethadol;

42 (10) Alpha-Methylfentanyl  
43 (N-[1-alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;  
44 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);

45 (11) Alpha-Methylthiofentanyl  
46 (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide  
47 );

48 (12) Benzethidine;



49 (13) Betacetylmethadol;

50 (14) Beta-Hydroxyfentanyl

51 (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

52 (15) Beta-Hydroxy-3-methylfentanyl

53 (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpr

54 opanamide);

55 (16) Beta-Hydroxythiofentanyl

56 (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpr

57 opionamide);

58 (17) Betameprodine;

59 (18) Betamethadol;

60 (19) Beta-Methyl fentanyl

61 (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide), also

62 known as  $\beta$ -methyl fentanyl;

63 (20) Beta'-Phenyl fentanyl

64 (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide), also

65 known as  $\beta'$ -phenyl fentanyl or 3-phenylpropanoyl fentanyl;

66 (21) Betaprodine;

67 (22) Brorphine (1-(1-(1-

68 (4-bromophenyl)ethyl)piperidin-4-yl)-

69 1,3-dihydro-2H-benzo[d]imidazol-2-one);

70 ( \* \* \*23) Butyrl fentanyl

71 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

72 ( \* \* \*24) Clonitazene;



73 ( \* \* \*25) Crotonyl fentanyl  
74 ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);  
75 ( \* \* \*26) Cyclopentyl fentanyl  
76 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);  
77 ( \* \* \*27) Cyclopropyl fentanyl  
78 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);  
79 ( \* \* \*28) Dextromoramide;  
80 ( \* \* \*29) Diampromide;  
81 ( \* \* \*30) Diethylthiambutene;  
82 ( \* \* \*31) Difenoxylin;  
83 ( \* \* \*32) Dimenoxadol;  
84 ( \* \* \*33) Dimepheptanol;  
85 ( \* \* \*34) Dimethylthiambutene;  
86 ( \* \* \*35) Dioxaphetyl butyrate;  
87 ( \* \* \*36) Dipipanone;  
88 ( \* \* \*37) Ethylmethylthiambutene;  
89 ( \* \* \*38) Etonitazene;  
90 ( \* \* \*39) Etoxeridine;  
91 ( \* \* \*40) Fentanyl carbamate  
92 (ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate);  
93 ( \* \* \*41) Fentanyl-related substances, meaning any  
94 substance not otherwise listed under another schedule and for  
95 which no exemption or approval is in effect under Section 505 of  
96 the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is



97 structurally related to fentanyl by one or more of the following  
98 modifications:

99 (A) Replacement of the phenyl portion of the  
100 phenethyl group by any monocycle, whether or not further  
101 substituted in or on the monocycle;

102 (B) Substitution in or on the phenethyl group with  
103 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro  
104 groups;

105 (C) Substitution in or on the piperidine ring with  
106 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,  
107 amino or nitro groups;

108 (D) Replacement of the aniline ring with any  
109 aromatic monocycle whether or not further substituted in or on the  
110 aromatic monocycle; and/or

111 (E) Replacement of the N-propionyl group by  
112 another acyl group.

113 ( \* \* \*42) 4-Fluoroisobutyryl fentanyl  
114 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide),  
115 also known as para-fluoroisobutyryl fentanyl);

116 ( \* \* \*43) 2'-Fluoro ortho-fluorofentanyl  
117 (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)  
118 propionamide), also known as 2'-fluoro 2-fluorofentanyl;

119 ( \* \* \*44) Furanyl fentanyl  
120 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

121 ( \* \* \*45) Furethidine;



122 ( \* \* \*46) Hydroxypethidine;

123 ( \* \* \*47) Isobutyryl fentanyl  
(N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

125 ( \* \* \*48) Isotonitazene (N,N-diethyl-2-(2-(4  
126 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);

127 ( \* \* \*49) Ketobemidone (including the optical and  
128 geometric isomers);

129 ( \* \* \*50) Levomoramide;

130 ( \* \* \*51) Levophenacylmorphane;

131 ( \* \* \*52) Methoxyacetyl fentanyl  
(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

133 ( \* \* \*53) 4'-Methyl acetyl fentanyl  
(N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);

135 ( \* \* \*54) 3-Methylfentanyl  
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);

137 ( \* \* \*55) 3-Methylthiofentanyl (N-[3-methyl-1-  
138 (2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide);

139 (56) Metonitazene  
140 (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)e  
141 than-1-amine (metonitazene));

142 ( \* \* \*57) Morpheridine;

143 ( \* \* \*58) MPPP  
(1-methyl-4-phenyl-4-propionoxypiperidine);

145 ( \* \* \*59) MT-45  
146 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);



147 ( \* \* \*60) Noracymethadol;  
148 ( \* \* \*61) Norlevorphanol;  
149 ( \* \* \*62) Normethadone;  
150 ( \* \* \*63) Norpipanone;  
151 ( \* \* \*64) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-  
152 (1-phenethylpiperidin-4-yl)acetamide);  
153 ( \* \* \*65) Ortho-Fluoroacryl fentanyl  
154 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);  
155 ( \* \* \*66) Ortho-Fluorobutyryl fentanyl  
156 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide), also  
157 known as 2-fluorobutyryl fentanyl;  
158 ( \* \* \*67) Ortho-Fluorofentanyl  
159 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide),  
160 also known as 2-fluorofentanyl;  
161 ( \* \* \*68) Ortho-Fluoroisobutyryl fentanyl  
162 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);  
163 ( \* \* \*69) Ortho-Methyl acetylfentanyl  
164 (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide), also  
165 known as 2-methyl acetylfentanyl;  
166 ( \* \* \*70) Ortho-Methyl methoxyacetyl fentanyl  
167 (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)  
168 acetamide), also known as 2-methyl methoxyacetyl fentanyl;  
169 ( \* \* \*71) Para-Chloroisobutyryl fentanyl  
170 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);



171 ( \* \* \*72) Para-Fluorobutyryl fentanyl  
172 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);  
173 ( \* \* \*73) Para-Fluorofentanyl (N-(4-fluorophenyl)  
174 -N-[1-(2-phenylethyl)-4-piperidinyl]propanamide);  
175 ( \* \* \*74) Para-Fluoro furanyl fentanyl  
176 N-(4-fluorophenyl)-N-  
177 (1-phenethylpiperidin-4-yl)furan-2-carboxamide);  
178 ( \* \* \*75) Para-Methoxybutyryl fentanyl  
179 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);  
180 ( \* \* \*76) Para-Methylfentanyl  
181 (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide),  
182 also known as 4-methylfentanyl);  
183 ( \* \* \*77) PEPAP  
184 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
185 ( \* \* \*78) Phenadoxone;  
186 ( \* \* \*79) Phenampromide;  
187 ( \* \* \*80) Phenomorphan;  
188 ( \* \* \*81) Phenoperidine;  
189 ( \* \* \*82) Phenyl fentanyl  
190 (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide), also known as  
191 benzoyl fentanyl;  
192 ( \* \* \*83) Piritramide;  
193 ( \* \* \*84) Proheptazine;  
194 ( \* \* \*85) Properidine;  
195 ( \* \* \*86) Propiram;





196 ( \* \* \*87) Racemoramide;  
197 ( \* \* \*88) Tetrahydrofuranyl fentanyl  
198 (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-  
199 carboxamide);  
200 ( \* \* \*89) Thiofentanyl  
201 (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);  
202 ( \* \* \*90) Thiofuranyl fentanyl  
203 (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide),  
204 also known as 2-thiofuranyl fentanyl or thiophene fentanyl;  
205 ( \* \* \*91) Tilidine;  
206 ( \* \* \*92) Trimeperidine;  
207 ( \* \* \*93) U-47700, (3,4-dichloro-N-  
208 [2-(dimethylamino)cyclohexyl]-N-methylbenzamide);  
209 ( \* \* \*94) Valeryl fentanyl  
210 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide).

211 (c) **Opium derivatives.** Unless specifically excepted or  
212 unless listed in another schedule, any of the following opium  
213 derivatives, their salts, isomers and salts of isomers, whenever  
214 the existence of these salts, isomers and salts of isomers is  
215 possible within the specific chemical designation:

- 216 (1) Acetorphine;
- 217 (2) Acetyldihydrocodeine;
- 218 (3) Benzylmorphine;
- 219 (4) Codeine methylbromide;
- 220 (5) Codeine-N-Oxide;



- 221 (6) Cyprenorphine;
- 222 (7) Desomorphine;
- 223 (8) Dihydromorphine;
- 224 (9) Drotebanol;
- 225 (10) Etorphine (except hydrochloride salt);
- 226 (11) Heroin;
- 227 (12) Hydromorphenol;
- 228 (13) Methyldesorphine;
- 229 (14) Methyldihydromorphine;
- 230 (15) Monoacetylmorphine;
- 231 (16) Morphine methylbromide;
- 232 (17) Morphine methylsulfonate;
- 233 (18) Morphine-N-Oxide;
- 234 (19) Myrophine;
- 235 (20) Nicocodeine;
- 236 (21) Nicomorphine;
- 237 (22) Normorphine;
- 238 (23) Pholcodine;
- 239 (24) Thebacon.

240 (d) **Hallucinogenic substances.** Unless specifically excepted  
241 or unless listed in another schedule, any material, compound,  
242 mixture or preparation which contains any quantity of the  
243 following substances, their salts, isomers (whether optical,  
244 positional, or geometric) and salts of isomers, whenever the



245 existence of these salts, isomers and salts of isomers is possible  
246 within the specific chemical designation:

- 247 (1) Alpha-ethyltryptamine;
- 248 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 249 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 250 (4) 2,5-dimethoxyamphetamine;
- 251 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 252 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine  
253 (2C-T-7);
- 254 (7) 4-methoxyamphetamine;
- 255 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 256 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 257 (10) 3,4-methylenedioxy amphetamine;
- 258 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 259 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known  
260 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl  
261 MDA, MDE, MDEA);
- 262 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also  
263 known as N-hydroxy MDA, N-OHMDA, and  
264 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 265 (14) 3,4,5-trimethoxy amphetamine;
- 266 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 267 (16) Alpha-methyltryptamine (also known as AMT);
- 268 (17) Bufotenine;
- 269 (18) Diethyltryptamine;



- 270 (19) Dimethyltryptamine;
- 271 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 272 (21) Ibogaine;
- 273 (22) Lysergic acid diethylamide (LSD);
- 274 (23) (A) Marijuana (Hemp as defined and regulated
- 275 under Sections 69-25-201 through 69-25-221 and Cannabidiol
- 276 contained in a legend drug product approved by the Federal Food
- 277 and Drug Administration or obtained under Section 41-29-136 are
- 278 exempt under Schedule I);
- 279 (B) Hashish;
- 280 (24) Mescaline;
- 281 (25) Parahexyl;
- 282 (26) Peyote;
- 283 (27) N-ethyl-3-piperidyl benzilate;
- 284 (28) N-methyl-3-piperidyl benzilate;
- 285 (29) Psilocybin;
- 286 (30) Psilocyn;
- 287 (31) Tetrahydrocannabinols, meaning
- 288 tetrahydrocannabinols contained in a plant of the genus Cannabis
- 289 (cannabis plant), as well as the synthetic equivalents of the
- 290 substances contained in the cannabis plant, or in the resinous
- 291 extractives of such plant, and/or synthetic substances,
- 292 derivatives, and their isomers with similar chemical structure and
- 293 pharmacological activity to those substances contained in the
- 294 plant such as the following:



- 295 (A) 1 cis or trans tetrahydrocannabinol;  
296 (B) 6 cis or trans tetrahydrocannabinol;  
297 (C) 3,4 cis or trans tetrahydrocannabinol.

298 (Since nomenclature of these substances is not  
299 internationally standardized, compounds of these structures,  
300 regardless of atomic positions, are covered.)

301 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)  
302 For purposes of this paragraph, tetrahydrocannabinols do not  
303 include hemp or hemp products regulated under Sections 69-25-201  
304 through 69-25-221.

305 However, the following products are exempted from control:

306 (i) THC-containing industrial products made  
307 from cannabis stalks (e.g., paper, rope and clothing);

308 (ii) Processed cannabis plant materials used  
309 for industrial purposes, such as fiber retted from cannabis stalks  
310 for use in manufacturing textiles or rope;

311 (iii) Animal feed mixtures that contain  
312 sterilized cannabis seeds and other ingredients (not derived from  
313 the cannabis plant) in a formula designed, marketed and  
314 distributed for nonhuman consumption;

315 (iv) Personal care products that contain oil  
316 from sterilized cannabis seeds, such as shampoos, soaps, and body  
317 lotions (if the products do not cause THC to enter the human  
318 body);



319 (v) Hemp as regulated under Sections  
320 69-25-201 through 69-25-221; and  
321 (vi) Any product derived from the hemp plant  
322 designed for human ingestion and/or consumption that is approved  
323 by the United States Food and Drug Administration;

324 (32) Phencyclidine;  
325 (33) Ethylamine analog of phencyclidine (PCE);  
326 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);  
327 (35) Thiophene analog of phencyclidine;  
328 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);  
329 (37) 4-methylmethcathinone (mephedrone);  
330 (38) 3,4-methylenedioxypropylvalerone (MDPV);  
331 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);  
332 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);  
333 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);  
334 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);  
335 or 2,5-dimethoxy-4-iodophenethylamine;  
336 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine  
337 (2C-T-2);  
338 (44)  
339 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);  
340 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);  
341 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);  
342 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine  
343 (2C-P);



344 (48) 3,4-methylenedioxy-N-methylcathinone (methyldone);  
345 (49)  
346 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
347 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);  
348 (50)  
349 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
350 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);  
351 (51)  
352 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or  
353 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;  
354 Cimbi-5);  
355 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,  
356 4-benzodiazepin-2-one (also known as Phenazepam);  
357 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,  
358 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene  
359 (also known as Etizolam);  
360 (54) Salvia divinorum;  
361 (55) Synthetic cannabinoids. Unless specifically  
362 excepted or unless listed in another schedule, any material,  
363 compound, mixture, or preparation which contains any quantity of a  
364 synthetic cannabinoid found in any of the following chemical  
365 groups, whether or not substituted to any extent, or any of those  
366 groups which contain any synthetic cannabinoid salts, isomers, or  
367 salts of isomers, whenever the existence of such salts, isomers,  
368 or salts of isomers is possible within the specific chemical



369 designation, including all synthetic cannabinoid chemical  
370 analogues in such groups:

371 (A) (6aR,10aR)-9-(hydroxymethyl)-6,  
372 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]  
373 chromen-1-ol (also known as HU-210 or  
374 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

375 (B) Naphthoylindoles and naphthylmethylindoles,  
376 being any compound structurally derived from 3-(1-naphthoyl)indole  
377 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted  
378 in the indole ring to any extent, or in the naphthyl ring to any  
379 extent;

380 (C) Naphthoylpyrroles, being any compound  
381 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not  
382 substituted in the pyrrole ring to any extent, or in the naphthyl  
383 ring to any extent;

384 (D) Naphthylmethylindenes, being any compound  
385 structurally derived from 1-(1-naphthylmethyl)indene, whether or  
386 not substituted in the indene ring to any extent or in the  
387 naphthyl ring to any extent;

388 (E) Phenylacetylindoles, being any compound  
389 structurally derived from 3-phenylacetylindole, whether or not  
390 substituted in the indole ring to any extent or in the phenyl ring  
391 to any extent;

392 (F) Cyclohexylphenols, being any compound  
393 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether





394 or not substituted in the cyclohexyl ring to any extent or in the  
395 phenolic ring to any extent;

396 (G) Benzoylindoles, whether or not substituted in  
397 the indole ring to any extent or in the phenyl ring to any extent;

398 (H) Adamantoylindoles, whether or not substituted  
399 in the indole ring to any extent or in the adamantoyl ring system  
400 to any extent;

401 (I) Tetrahydro derivatives of cannabinal and  
402 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,  
403 except where contained in cannabis or cannabis resin;

404 (J) 3-Cyclopropylmethanone indole or  
405 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by  
406 substitution at the nitrogen atom of the indole ring, whether or  
407 not further substituted in the indole ring to any extent, whether  
408 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl  
409 rings to any extent;

410 (K) Quinoliny ester indoles, being any compound  
411 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny  
412 ester, whether or not substituted in the indole ring to any extent  
413 or the quinolone ring to any extent;

414 (L) 3-carboxamide-1H-indazoles, whether or not  
415 substituted in the indazole ring to any extent and substituted to  
416 any degree on the carboxamide nitrogen and  
417 3-carboxamide-1H-indoles, whether or not substituted in the indole



418 ring to any extent and substituted to any degree on the  
419 carboxamide nitrogen;

420 (M) Cycloalkanemethanone Indoles, whether or not  
421 substituted at the nitrogen atom on the indole ring, whether or  
422 not further substituted in the indole ring to any extent, whether  
423 or not substituted on the cycloalkane ring to any extent;

424 (56) Naphthalen-1-yl  
425 1-(5-fluoropentyl)-1H-indole-3-carboxylate, also known as NM2201  
426 or CBL2201;

427 (57) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
428 pyrrolo[2,3-b]pyridine-3-carboxamide, also known as  
429 5F-CUMYL-P7AICA or SGT-25;

430 (58) Methyl  
431 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutano  
432 ate, also known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA);

433 (59) 1-(4-methoxyphenyl)-N-methylpropan-2-amine, also  
434 known as para-methoxymethamphetamine or PMMA;

435 (60) Ethyl 2-(1-(5-fluoropentyl)  
436 -1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, also known as  
437 5F-EDMB-PINACA;

438 (61) Methyl  
439 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoa  
440 te, also known as 5F-MDMB-PICA or 5F-MDMB-2201;

441 (62)  
442 N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,



443 also known as FUB-AKB48 or FUB-APINACA or AKB48  
444 N-(4-fluorobenzyl);  
445 (63)  
446 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)  
447 methanone, also known as FUB-144;  
448 (64) N-ethylhexedrone, also known as  
449  $\alpha$ -ethylaminohexanophenone or 2-(ethylamino)-1-phenylhexan-1-one;  
450 (65) Alpha-pyrrolidinohexanophenone, also known as  
451  $\alpha$ -PHP or  $\alpha$ -pyrrolidinohexanophenone or  
452 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);  
453 (66) 4-methyl-alpha-ethylaminopentiophenone, also known  
454 as 4-MEAP or 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);  
455 (67) 4'-methyl-alpha-pyrrolidinohexiophenone, also  
456 known as MPHP or 4'-methyl-alpha-pyrrolidinohexanophenone or  
457 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);  
458 (68) Alpha-pyrrolidinoheptaphenone (also known as PV8;  
459 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);  
460 (69) 4'-chloro-alpha-pyrrolidinovalerophenone, also  
461 known as 4-chloro- $\alpha$ -PVP or 4'-chloro- $\alpha$ -pyrrolidinopentiophenone or  
462 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);  
463 (70)  
464 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one, also known as  
465 methoxetamine or MXE \* \* \*;  
466 (71) Zipeprol



467 (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylp  
468 ropan-2-ol); and

469 (72) Eutylone

470 (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one).

471 (e) **Depressants.** Unless specifically excepted or unless  
472 listed in another schedule, any material, compound, mixture, or  
473 preparation which contains any quantity of the following  
474 substances having a depressant effect on the central nervous  
475 system, including their salts, isomers, and salts of isomers,  
476 whenever the existence of such salts, isomers, and salts of  
477 isomers is possible within the specific chemical designation:

478 (1) Clonazepam,

479 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]  
480 benzodiazepine;

481 (2) Flualprazolam,

482 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4  
483 ]benzodiazepine;

484 (3) Flubromazepam,

485 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;

486 (4) Flubromazolam,

487 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]  
488 benzodiazepine;

489 (5) Gamma-hydroxybutyric acid (other names include:

490 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic  
491 acid; sodium oxybate; sodium oxybutyrate);



492 (6) Mecloqualone;

493 (7) Methaqualone.

494 (f) **Stimulants.** Any material, compound, mixture or  
495 preparation which contains any quantity of the following central  
496 nervous system stimulants including optical salts, isomers and  
497 salts of isomers unless specifically excepted or unless listed in  
498 another schedule:

499 (1) Aminorex;

500 (2) Amineptine

501 (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic  
502 acid);

503 ( \* \* \*3) N-benzylpiperazine (also known as BZP and  
504 1-benzylpiperazine);

505 ( \* \* \*4) Cathinone;

506 ( \* \* \*5) 4,4'-Dimethylaminorex, also known as  
507 4,4'-DMAR or

508 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine;

509 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);

510 ( \* \* \*6) Fenethylamine;

511 (7) Mesocarb

512 (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-  
513 ium-5-yl) carbamimidate);

514 ( \* \* \*8) Methcathinone;

515 (9) Methiopropamine

516 (N-methyl-1-(thiophen-2-yl)propan-2-amine));



517 ( \* \* \*10) 4-methylaminorex (also known as  
518 2-amino-4-methyl-5-phenyl-2-oxazoline);

519 ( \* \* \*11) N-ethylamphetamine;

520 ( \* \* \*12) Any material, compound, mixture or  
521 preparation which contains any quantity of  
522 N,N-dimethylamphetamine. (Other names include:  
523 N,N,-alpha-trimethyl-benzeneethanamine and  
524 N,N-alpha-trimethylphenethylamine);

525 ( \* \* \*13) Synthetic cathinones. (A) Unless listed in  
526 another schedule, any compound other than bupropion that is  
527 structurally derived from 2-Amino-1-phenyl-1-propanone by  
528 modification in any of the following ways:

529 (i) By substitution in the phenyl ring to any  
530 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide  
531 substituents, whether or not further substituted in the phenyl  
532 ring by one or more other univalent substituents;

533 (ii) By substitution at the 3-position with  
534 an alkyl substituent;

535 (iii) By substitution at the nitrogen atom  
536 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom  
537 in a cyclic structure.

538 (B) The compounds covered in this paragraph (10)  
539 include, but are not limited to, any material, compound, mixture  
540 or preparation which contains any quantity of a synthetic  
541 cathinone found in any of the following compounds, whether or not



542 substituted to any extent, or any of these compounds which contain  
543 any synthetic cathinone, or salts, isomers, or salts of isomers,  
544 whenever the existence of such salts, isomers or salts of isomers  
545 is possible, unless specifically excepted or listed in another  
546 schedule:

547 (i) 4-methyl-N-ethylcathinone ("4-MEC");

548 (ii) 4-methyl-alpha-pyrrolidinopropiophenone  
549 ("4-MePPP");

550 (iii) Alpha-pyrrolidinopentiophenone  
551 (" $\alpha$ -PVP");

552 (iv) 1-(1,3-benzodioxol-5-yl)-2-  
553 (methylamino)butan-1-one ("butylone");

554 (v) 2-(methylamino)-1-phenylpentan-1-one  
555 ("pentedrone");

556 (vi) 1-(1,3-benzodioxol-5-yl)-2-  
557 (methylamino)pentan-1-one ("pentylone");

558 (vii) 4-fluoro-N-methylcathinone ("4-FMC");

559 (viii) 3-fluoro-N-methylcathinone ("3-FMC");

560 (ix) 1-(naphthalen-2-yl)-2- (pyrrolidin-1-yl)  
561 pentan-1-one ("naphyrone");

562 (x) Alpha-pyrrolidinobutiophenone (" $\alpha$ -PBP");

563 and

564 (xi) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)  
565 -pentan-1-one (N-ethylpentylone, ephylone).







- 591 (4) Brexanolone;
- 592 (5) Bromazepam;
- 593 (6) Camazepam;
- 594 (7) Carisoprodol;
- 595 (8) Chloral betaine;
- 596 (9) Chloral hydrate;
- 597 (10) Chlordiazepoxide and its salts, but does not  
598 include chlordiazepoxide hydrochloride and clidinium bromide or  
599 chlordiazepoxide and esterified estrogens;
- 600 (11) Clobazam;
- 601 (12) Clonazepam;
- 602 (13) Clorazepate;
- 603 (14) Clotiazepam;
- 604 (15) Cloxazolam;
- 605 (16) Daridorexant  
606 ([(S)-2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-  
607 methylpyrrolidin-1-yl](5-methoxy-2-(2H-1,2,3-triazol-2-  
608 yl)phenyl)methanone), including its salts, isomers, and salts of  
609 isomers;
- 610 ( \* \* \*17) Delorazepam;
- 611 ( \* \* \*18) Diazepam;
- 612 ( \* \* \*19) Dichloralphenazone;
- 613 ( \* \* \*20) Estazolam;
- 614 ( \* \* \*21) Ethchlorvynol;
- 615 ( \* \* \*22) Ethinamate;



616 ( \* \* \*23) Ethyl loflazepate;  
617 ( \* \* \*24) Fludiazepam;  
618 ( \* \* \*25) Flunitrazepam;  
619 ( \* \* \*26) Flurazepam;  
620 ( \* \* \*27) Fospropofol;  
621 ( \* \* \*28) Halazepam;  
622 ( \* \* \*29) Haloxazolam;  
623 ( \* \* \*30) Ketazolam;  
624 ( \* \* \*31) Lemborexant;  
625 ( \* \* \*32) Loprazolam;  
626 ( \* \* \*33) Lorazepam;  
627 ( \* \* \*34) Lormetazepam;  
628 ( \* \* \*35) Mebutamate;  
629 ( \* \* \*36) Medazepam;  
630 ( \* \* \*37) Meprobamate;  
631 ( \* \* \*38) Methohexital;  
632 ( \* \* \*39) Methylphenobarbital;  
633 ( \* \* \*40) Midazolam;  
634 ( \* \* \*41) Nimetazepam;  
635 ( \* \* \*42) Nitrazepam;  
636 ( \* \* \*43) Nordiazepam;  
637 ( \* \* \*44) Oxazepam;  
638 ( \* \* \*45) Oxazolam;  
639 ( \* \* \*46) Paraldehyde;  
640 ( \* \* \*47) Petrichloral;



641 ( \* \* \*48) Phenobarbital;  
642 ( \* \* \*49) Pinazepam;  
643 ( \* \* \*50) Prazepam;  
644 ( \* \* \*51) Quazepam;  
645 ( \* \* \*52) Remimazolam;  
646 ( \* \* \*53) Suvorexant;  
647 ( \* \* \*54) Temazepam;  
648 ( \* \* \*55) Tetrazepam;  
649 ( \* \* \*56) Triazolam;  
650 ( \* \* \*57) Zaleplon;  
651 ( \* \* \*58) Zolpidem;  
652 ( \* \* \*59) Zopiclone.

653 (c) \* \* \* [Deleted]

654 (d) **Lorcaserin.** Any material, compound, mixture, or  
655 preparation which contains any quantity of Lorcaserin, including  
656 its salts, isomers, and salts of such isomers, whenever the  
657 existence of such salts, isomers, and salts of isomers is  
658 possible.

659 (e) **Stimulants.** Any material, compound, mixture or  
660 preparation which contains any quantity of the following  
661 substances:

- 662 (1) Cathine ((+/-) Norpseudoephedrine);  
663 (2) Diethylpropion;  
664 (3) Fencamfamin;  
665 (4) Fenproporex;



- 666 (5) Mazindol;  
667 (6) Mefenorex;  
668 (7) Modafinil;  
669 (8) Pemoline (including any organometallic  
670 complexes and chelates thereof);  
671 (9) Phentermine;  
672 (10) Pipradrol;  
673 (11) Serdexmethylphenidate;  
674 (12) Sibutramine;  
675 (13) Solriamfetol;  
676 (14) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

677 (f) **Other substances.**

- 678 (1) Pentazocine;  
679 (2) Butorphanol (including its optical isomers);  
680 (3) Eluxadoline

681 (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopr  
682 opyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-meth  
683 oxybenzoic acid); (including its optical isomers) and its salts,  
684 isomers, and salts of isomers \* \* \*;

685 (4) Zuranolone and its salts, isomers, and salts  
686 of isomers.

687 (B) Any material, compound, mixture or preparation which  
688 contains any quantity of a Schedule IV controlled substance and is  
689 listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24,



690 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions  
691 of the Uniform Controlled Substances Law.

692 **SECTION 3.** Section 41-29-121, Mississippi Code of 1972, is  
693 amended as follows:

694 41-29-121.

695 **SCHEDULE V**

696 (a) Schedule V consists of the drugs and other substances,  
697 by whatever official name, common or usual name, chemical name, or  
698 brand name designated, listed in this section.

699 (b) Narcotic drugs. [Reserved]

700 (c) **Narcotic drugs containing nonnarcotic active medicinal**  
701 **ingredients.** Any compound, mixture or preparation containing any  
702 of the following narcotic drugs, or their salts calculated as the  
703 free anhydrous base or alkaloid, in limited quantities as set  
704 forth below, which also contains one or more nonnarcotic active  
705 medicinal ingredients in sufficient proportion to confer upon the  
706 compound, mixture or preparation valuable medicinal qualities  
707 other than those possessed by the narcotic drug alone:

708 (1) Not more than two hundred (200) milligrams of  
709 codeine, or any of its salts, per one hundred (100) milliliters or  
710 per one hundred (100) grams;

711 (2) Not more than one hundred (100) milligrams of  
712 dihydrocodeine, or any of its salts, per one hundred (100)  
713 milliliters or per one hundred (100) grams;



714 (3) Not more than one hundred (100) milligrams of  
715 ethylmorphine, or any of its salts, per one hundred (100)  
716 milliliters or per one hundred (100) grams;

717 (4) Not more than two and five-tenths (2.5) milligrams  
718 of diphenoxylate and not less than twenty-five (25) micrograms of  
719 atropine sulphate per dosage unit;

720 (5) Not more than one hundred (100) milligrams of opium  
721 per one hundred (100) milliliters or per one hundred (100) grams;

722 (6) Not more than five-tenths (0.5) milligram of  
723 difenoxin and not less than twenty-five (25) micrograms of  
724 atropine sulfate per dosage unit.

725 (d) **Stimulants.** Unless specifically excepted or listed in  
726 another schedule, any material, compound, mixture or preparation  
727 which contains any quantity of the following substance, including  
728 its salts, isomers and salts of isomers: Pyrovalerone.

729 (e) **Depressants.** Unless specifically exempted or excluded  
730 or unless listed in another schedule, any material, compound,  
731 mixture or preparation which contains any quantity of the  
732 following substances having a depressant effect on the central  
733 nervous system, including their salts, isomers and salts of  
734 isomers:

735 (1) Brivaracetam  
736 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also  
737 referred to as BRV; UCB-34714; Briviact);



738 (2) Cenobamate  
739 ([ (1R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl] carbamate;  
740 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate  
741 (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)  
742 -2-(2H-tetrazol-2-yl)ethyl ester);

743 (3) Ezogabine [N-[2-amino-4-(4-  
744 fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];

745 (4) Ganaxolone  
746 (3a-hydroxy-3b-methyl-5a-pregnan-20-one);

747 ( \* \* \*5) Lacosamide  
748 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];

749 ( \* \* \*6) Lasmiditan [2,4,6-trifluoro-N-(6-  
750 (1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide];

751 ( \* \* \*7) Pregabalin  
752 [(S)-3-(aminomethyl)-5-methylhexanoic acid].

753 (f) Any material, compound, mixture or preparation which  
754 contains any quantity of a Schedule V controlled substance and is  
755 listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24,  
756 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions  
757 of the Uniform Controlled Substances Law.

758 **SECTION 4.** This act shall take effect and be in force from  
759 and after July 1, 2024.

